Thromb Haemost 2016; 116(03): 578-580
DOI: 10.1160/TH16-01-0025
Letters to the Editor
Schattauer GmbH

Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation

Matthew R. Wilson
1   Department of Haematology, Royal Infirmary, Glasgow, UK
,
Ruwan Parakramawansha
2   Department of Clinical Pharmacology, Royal Infirmary, Glasgow, UK
,
Terence J. Quinn
3   Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
,
Robert C. Tait
1   Department of Haematology, Royal Infirmary, Glasgow, UK
3   Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
› Author Affiliations
Further Information

Publication History

Received: 09 January 2016

Accepted after major revision: 13 May 2016

Publication Date:
11 November 2017 (online)

Supplementary Material to this article is available online at www.thrombosis-online.com.

 
  • References

  • 1 White HD, Gruber M, Feyzi J. et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
  • 2 National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 180 Issued June 2014; 1-5 2015.
  • 3 Landefeld CS, Goldman L.. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
  • 4 Costa GL, Lamego RM, Colosimo EA. et al. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther 2012; 34: 1511-1520.
  • 5 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-1563.
  • 6 Rose AJ, Hylek EM, Ozonoff A. et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-2191.
  • 7 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
  • 8 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144: 1555-1563.
  • 9 Abdul-Rahim AH, Wong J, McAlpine C. et al. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. Heart 2014; 100: 557-562.